Generic exenatide reaches US pharmacies

Federal drug records show that on Nov. 22, 2024, Amneal Pharmaceuticals LLC began marketing a generic exenatide injection product under ANDA 206697, listed in the FDA's National Drug Code directory as "Exenatide," a 250 mcg/mL solution supplied in a prefilled cartridge for subcutaneous injection ^[1]. The FDA record lists Amneal as the labeler and shows a marketing start date of Nov. 22, 2024, with the listing's marketing end date set for June 30, 2027 ^[1].

This appears to be the same product the FDA referenced in a Dec. 23, 2024 press release, which stated that the agency "approved the first generic in this class of medications last month with the approval of a generic referencing Byetta (exenatide)" — meaning November 2024 ^[2]. That announcement was actually about a separate approval: the first generic version of Victoza (liraglutide), a once-daily GLP-1 injection for type 2 diabetes, granted to Hikma Pharmaceuticals USA Inc. ^[2].

The FDA release noted that liraglutide injection and "certain other GLP-1 medications" were in shortage at the time, and that the agency prioritizes review of generic drug applications for medicines in shortage to help improve patient access ^[2]. The agency also cited Centers for Disease Control and Prevention figures showing more than 38 million Americans have diabetes, with 90% to 95% of those cases being type 2 ^[2].

The FDA data available does not specify whether Amneal's product is offered in the same 5 mcg and 10 mcg per-dose strengths historically associated with Byetta, and it does not address whether any generic exists for the once-weekly, extended-release exenatide product sold as Bydureon. The openFDA search used here returned 13 total exenatide-related records, but only one was reviewed in detail, so it is not established from these sources whether an extended-release generic is or is not available ^[1].

Why it matters for patients

For people prescribed twice-daily exenatide, a generic option on pharmacy shelves is significant because generic drugs are "generally more affordable," according to the FDA's Office of Generic Drugs ^[2]. The agency has said expanding generic competition for GLP-1 drugs is part of its broader effort to improve access to these medicines, particularly during periods when brand-name or other GLP-1 products have been in short supply ^[2].

However, patients using the once-weekly extended-release exenatide product should be aware that the sources reviewed here do not confirm a generic version exists for that formulation. Anyone relying on either version of exenatide, or considering a switch, would need to check with a pharmacist or manufacturer about current availability, since FDA listings show product-specific marketing windows that can change ^[1].

It's also worth noting that this generic exenatide approval was reported by the FDA as a precursor step: the agency described it as the first in a sequence that led to the approval of generic liraglutide the following month, suggesting continued regulatory attention to expanding generic GLP-1 options ^[2].

What happens next

The FDA approved the first generic liraglutide injection, referencing Victoza, on Dec. 23, 2024, granting it to Hikma Pharmaceuticals USA Inc.; the agency directed patients to contact the manufacturer for details on availability ^[2]. The FDA has said it continues to fund research and issue industry guidance to support development of complex generic drugs, including GLP-1 medications, as part of its Drug Competition Action Plan ^[2]. No information in the sources reviewed indicates a specific date for any future generic approval covering the once-weekly extended-release exenatide product.